Fintech
Synthetix Ends the SNX Token Inflation and Starts Focusing on Buybacks
Synthetix plays an essential role in the decentralized derivatives trading ecosystem. With liquidity pools that currently include a total value of over $890M across the Ethereum network and the Optimism Layer 2 network, Synthetix is at the forefront of innovation in the DeFi world. The decision to end SNX token inflation is a bold move, that has the potential to fundamentally change the dynamics of the token
The crypto world never stands still, and a recent example of this is the decision by Synthetix, a leading derivatives platform, to end the inflation of their SNX token. In a remarkable turn of events, the Synthetix user community has adopted a governance proposal, SIP-2043, aimed at stopping the inflation of the SNX token.
Read more about Synthetix and find the latest business news of the day with our companion app Born2Invest.
The End of Inflation: A New Beginning for Synthetix
The decision to end inflation is a crucial step for Synthetix. Originally, inflationary rewards were introduced to encourage liquidity and growth. However, the core team has found that these incentives have become less effective over time. This marks a significant shift in the project’s strategy, away from inflation and towards a model focused on token buybacks and burns.
New strategies: buybacks and burns
Synthetix’s upcoming Andromeda software update will usher in a new era. The platform plans to use trading fees for SNX token buybacks and burns. This means a reduction in token supply by using protocol-generated fees to acquire and destroy SNX tokens. Such a strategy could tighten supply and potentially increase value for existing token holders.
Impact on stakers and the market
For Synthetix stakers, this change means that they will no longer have to claim weekly inflationary token rewards. The market has already responded positively to this development.
Following the announcement, the Synthetix token has risen to its high for the year and is now trading at $4.75 – up 8% on the day, with a total supply of around 328 million and a fully diluted market capitalization of $1.5 billion.
Synthetix: A Strong Player in Decentralized Derivatives Trading
Synthetix plays an essential role in the decentralized derivatives trading ecosystem. With liquidity pools that currently include a total value of over $890 million across the Ethereum network and the Optimism Layer 2 network, Synthetix is at the forefront of innovation in the DeFi world.
Summary
The decision to end SNX token inflation is a bold move by Synthetix that has the potential to fundamentally change the dynamics of the token and the protocol as a whole. As the market continues to evolve and mature, such strategic decisions could pave the way for the future of DeFi.
__
(Featured image by geralt via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in BLOCK-BUILDERS.DE. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us
-
Biotech2 weeks ago
Rovi Cuts Its Profit by 4% in the First Nine Months, to 113.5 Million
-
Biotech4 days ago
Better Care Advances Healthcare Technology with Partnership with Oracle
-
Fintech1 week ago
Fintech Company Satispay Raises 60 Million Euros Led by Addition
-
Biotech2 days ago
ATB Therapeutics Raises €54 Million and Attracts a Pharmaceutical Giant